1-13 of 13
Timothy J Bell
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Patient-Focused Benefits of at-Home Versus in-Clinic Administration of Cancer Therapy: New Considerations for the COVID-19 Era

Karen E. Sandman, PhD, Timothy J. Bell
Journal: Blood
Blood (2020) 136 (Supplement 1): 35–36.
https://doi.org/10.1182/blood-2020-137560
Published: 2020
Journal Articles

Comparative Effectiveness of Glasdegib or Venetoclax in Combination with Low-Dose Cytarabine Using Simulated Treatment Comparisons

Gabriel Tremblay, DBA, MSc, BS, Patrick Daniele, Mike Dolph, MSc BHSc, Timothy J. Bell, Geoffrey Chan, MD, Andrew Brown, PhD, Joseph C Cappelleri, PhD MPH, MS
Journal: Blood
Blood (2020) 136 (Supplement 1): 17–18.
https://doi.org/10.1182/blood-2020-137641
Published: 2020
Journal Articles

Patterns of Undertreatment Among Patients with Acute Myeloid Leukemia (AML) Not Receiving Standard Intensive Induction Chemotherapy

Elizabeth Hubscher, Slaven Sikirica, Timothy J. Bell, Andrew Brown, PhD, Verna L Welch, PhD MPH, Alexander Russell-Smith, MSc, Paul G D'Amico, PhDRN,NP
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–19.
https://doi.org/10.1182/blood-2020-137425
Published: 2020
Journal Articles

Treatment Decision Making in AML: Factors of Importance to Clinicians, AML Patients and Their Family

Thomas W. LeBlanc, MDMA,MHS, Roland B. Walter, MD PhD MS, Loriana Hernandez-Aldama, Kate Sully, PhD, Timothy J Bell, MHA, Chloe Johnson, Francois Peloquin, MSc, Adam Gater, Verna L Welch, PhD MPH, Louise O'Hara, Ryan Hohman, Diana Merino, Nigel H. Russell, MD, Neil Horikoshi, Dawn Maze, MDFRCPC,MSc
Journal: Blood
Blood (2019) 134 (Supplement_1): 3498.
https://doi.org/10.1182/blood-2019-124660
Published: 2019
Journal Articles

Budget Impact of Glasdegib in Combination with Low-Dose Cytarabine for the Treatment of First-Line Acute Myeloid Leukemia in the United States

Ha Anh Pham, MSc, Sandra Milev, Shujun Li, Denise Zou, Yannan Hu, PhD, Bart Heeg, PhD, Timothy J Bell, MHA
Journal: Blood
Blood (2019) 134 (Supplement_1): 5852.
https://doi.org/10.1182/blood-2019-122709
Published: 2019
Journal Articles

Overall Survival of Glasdegib in Combination with Low-Dose Cytarabine and Azacitidine By Bone Marrow Blasts Among Adult Patients with Previously Untreated Acute Myeloid Leukemia: Comparative Effectiveness Using Indirect Treatment Comparisons

Sophie Van Beekhuizen, MSc, Timothy J Bell, MHA, Ana Gezin, MSc, Joseph C Cappelleri, PhD MPH, MS, Bart Heeg, PhD, Carl Selya-Hammer, MSc, Majed Charaan, MSc, MBA, Geoffrey Chan, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5846.
https://doi.org/10.1182/blood-2019-125852
Published: 2019
Journal Articles

Quality-Adjusted Survival for Low-Dose Cytarabine (LDAC) Versus Glasdegib+LDAC Among Newly Diagnosed Acute Myeloid Leukemia Patients Who Are Not Candidates for Intensive Chemotherapy: A Q-TWiST Analysis

Youngmin Kwon, BA, Timothy J Bell, MHA, Caitlyn Solem, PhD, Joseph C Cappelleri, PhD MPH, MS, Courtney Johnson, MPH, Helen Bhattacharyya, PhD, Caroline J. Hoang, PhD, Jorge E. Cortes, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2610.
https://doi.org/10.1182/blood-2019-126672
Published: 2019
Journal Articles

Clinical Responses of Glasdegibplus Low-Dose Ara-C, Azacitidine, and Decitabine Among Acute Myeloid Leukemia (AML) Patients Ineligible to Receive Intensive Chemotherapy: Comparative Effectiveness Using Indirect Treatment Comparison (ITC) Methods

Tracy Westley, MPH, Anna Forsythe, PharmD, MSc, MBA, Timothy J Bell, Joseph C Cappelleri, PhD MPH, MS, Gabriel Tremblay, DBA, MSc, BS, Geoffrey Chan, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2709.
https://doi.org/10.1182/blood-2018-99-111931
Published: 2018
Journal Articles

Treatment in AML and MDS Patients Who Are Ineligible for Intensive Chemotherapy: Using Social Media Intelligence to Capture What Really Matters to Patients

Alison Booth, MSc, Timothy J Bell, Sonia Halhol, MSc, Shiyu Pan, MSc, Verna L Welch, PhD MPH, CPEHR, CPHIMS, Evie Merinopoulou, MSc, Dimitra Lambrelli, PhD, Andrew Cox, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4826.
https://doi.org/10.1182/blood-2018-99-112827
Published: 2018
Journal Articles

Comparative Effectiveness of Combination Glasdegib+ Low-Dose Cytarabine (GLAS+LDAC) Vs Combination Venetoclax + Low-Dose Cytarabine (VEN+LDAC) Among Older Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (NIC): Indirect Treatment Comparison (ITC) Methods

Tracy Westley, MPH, Anna Forsythe, PharmD, MSc, MBA, Timothy J Bell, Joseph C Cappelleri, PhD MPH, MS, Geoffrey Chan, MD, Gabriel Tremblay, DBA, MSc, BS
Journal: Blood
Blood (2018) 132 (Supplement 1): 1429.
https://doi.org/10.1182/blood-2018-99-111971
Published: 2018
Journal Articles

Using Social Media to Highlight Unmet Needs in Patients with AML and MDS Ineligible for Intensive Chemotherapy: A Patient Centered Perspective

Alison Booth, MSc, Timothy J Bell, Sonia Halhol, MSc, Shiyu Pan, MSc, Verna L Welch, PhD MPH, CPEHR, CPHIMS, Evie Merinopoulou, MSc, Dimitra Lambrelli, PhD, Andrew Cox, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4831.
https://doi.org/10.1182/blood-2018-99-112922
Published: 2018
Journal Articles

A Patient-Centred Approach to Understanding the Trade-Offs Associated with Treatment Decision Making in Hematological Cancers with Short Life Expectancy

Chloe Johnson, Timothy J Bell, Kate Sully, PhD, Verna L Welch, PhD MPH, CPEHR, CPHIMS, Francois Peloquin, BS, Adam Gater
Journal: Blood
Blood (2018) 132 (Supplement 1): 5899.
https://doi.org/10.1182/blood-2018-99-116226
Published: 2018
Journal Articles

Patient-Centered Insights on Living with Acute Myeloid Leukemia and Its Treatments Using Patient Reported Information Shared Via Social Media

Sigrid Rebecca Crawford, MA, Timothy J Bell, Rebecca Rushton, MSc, Lynda Doward, MRes
Journal: Blood
Blood (2018) 132 (Supplement 1): 5907.
https://doi.org/10.1182/blood-2018-99-112427
Published: 2018